RVPH - REVIVA PHARMACEUTICALS HOLDINGS, INC.
IEX Last Trade
1.835
0.095 5.177%
Share volume: 497
Last Updated: Thu 26 Dec 2024 03:30:21 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$1.74
0.10
5.46%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
32.84%
1 Month
54.78%
3 Months
37.98%
6 Months
41.27%
1 Year
-61.64%
2 Year
-44.55%
Key data
Stock price
$1.84
DAY RANGE
$1.74 - $1.74
52 WEEK RANGE
$0.69 - $5.67
52 WEEK CHANGE
-$65.37
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Laxminarayan Bhat
Region: US
Website: revivapharma.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: revivapharma.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia. RP1208 that is in pre-clinical development studies for depression and obesity.
Recent news